{
  "id": "5c72aaed7c78d6947100006f",
  "type": "yesno",
  "question": "Is pazopanib an effective treatment of glioblastoma?",
  "ideal_answer": "No. Pazopanib does not improve survival of glioblastoma patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/20200024",
    "http://www.ncbi.nlm.nih.gov/pubmed/23363814"
  ],
  "snippets": [
    {
      "text": "RESULTS: The six-month progression-free survival (PFS) rates in phase II (n = 41) were 0% and 15% in the PTEN/EGFRvIII-positive and PTEN/EGFRvIII-negative cohorts, respectively, leading to early termination. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23363814",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Single-agent pazopanib did not prolong PFS in this patient population but showed in situ biological activity as demonstrated by radiographic responses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20200024",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}